Indication

Granulomatosis with polyangiitis

Granulomatosis with polyangiitis is a rare, systemic autoimmune disease classified within the spectrum of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitides. Read more about Granulomatosis with polyangiitis

5 drugs 5 manufacturers

Advertisement

Drugs that treat it

Common Granulomatosis with polyangiitis therapies.

Showing 1–5 of 5 drugs

RITUXAN (rituximab)

ANTINEOPLASTIC MONOCLONAL ANTIBODIES·RELAPSE OR REFRACTORY NON-HODGKIN'S LYMPHOMA·+10
GENENTECH

TRUXIMA (rituximab-abbs)

ANTINEOPLASTIC MONOCLONAL ANTIBODIES·RELAPSE OR REFRACTORY NON-HODGKIN'S LYMPHOMA·+7
CEPHALON,INC.

RUXIENCE (rituximab-pvvr)

ANTINEOPLASTIC MONOCLONAL ANTIBODIES·RELAPSE OR REFRACTORY NON-HODGKIN'S LYMPHOMA·+7
Parke-Davis Pfizer

TAVNEOS (avacopan)

COMPLEMENT INHIBITORS·GRANULOMATOSIS WITH POLYANGIITIS·+1
CHEMOCENTRYX/AM
Filter & compare in the drug finder →Opens the drug finder with Granulomatosis with polyangiitis preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Granulomatosis with polyangiitis.

Granulomatosis with polyangiitis is a rare, systemic autoimmune disease classified within the spectrum of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitides.

It predominantly affects adults, although it can manifest at any age, and characteristically targets the upper and lower respiratory tracts along with the kidneys.

Pathophysiologically, the condition is defined by necrotizing granulomatous inflammation of tissue and necrotizing vasculitis of small- to medium-sized blood vessels.

Common clinical manifestations include chronic destructive rhinosinusitis, pulmonary nodules or cavitary lesions, and rapidly progressive, pauci-immune crescentic glomerulonephritis.

Personalize your experience

Follow Granulomatosis with polyangiitis and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it